Pluristem

Pluristem launches Phase I clinical trial to treat tendonitis with stem cells

Pluristem launches Phase I clinical trial to treat tendonitis with stem cells

Mass Device

The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy

The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy

Seeking Alpha

Pluristem Gets FDA's Orphan Drug Nod for Anemia Treatment

Pluristem Gets FDA's Orphan Drug Nod for Anemia Treatment

Motley Fool

Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine

Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine

Seeking Alpha

Here are 5 Biopharmaceutical Companies on the Rise

Here are 5 Biopharmaceutical Companies on the Rise

Wall St Cheat Street

The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market

The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market

Seeking Alpha

Pluristem prices public offering of 8 mln units at $4/shr

Pluristem prices public offering of 8 mln units at $4/shr

Reuters

Pluristem to Begin IC Phase II Trial

Pluristem to Begin IC Phase II Trial

Yahoo/Zacks

Stem Cell Therapy Outlook Starting To Match Clinical Results

Stem Cell Therapy Outlook Starting To Match Clinical Results

Seeking Alpha

Pluristem's Cell Therapy For Bone Marrow A Blockbuster In The Making

Pluristem's Cell Therapy For Bone Marrow A Blockbuster In The Making

Seeking Alpha